LifeMD, Inc. (NASDAQ:LFMD) Stock Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Analysts rate LifeMD a “Moderate Buy”: eight of ten analysts recommend buying the stock, while one rates it a hold and one a sell. The average 12-month price target is $7.57.
• LifeMD shares opened at $2.12, near their 52-week low of $2.06, with a market capitalization of approximately $102 million. The stock trades below both its 50-day and 200-day moving averages.
• The company reported a quarterly loss of $0.16 per share, slightly worse than estimates, while revenue of $47.28 million also fell short of expectations. Institutional investors and hedge funds own approximately 35.5% of the shares.

Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.57.

A number of equities analysts have recently issued reports on LFMD shares. Zacks Research upgraded shares of LifeMD from a "strong sell" rating to a "hold" rating in a research report on Monday, August 17th. KeyCorp set a $5.00 target price on shares of LifeMD and gave the company an "overweight" rating in a report on Friday, August 7th. B. Riley Financial started coverage on shares of LifeMD in a report on Friday, September 11th. They issued a "buy" rating and a $8.00 target price on the stock. Wall Street Zen downgraded shares of LifeMD from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of LifeMD in a research note on Tuesday, August 4th.

LifeMD Stock Performance

Shares of LFMD stock opened at $2.12 on Wednesday. The stock's 50-day moving average is $2.88 and its two-hundred day moving average is $3.68. The firm has a market cap of $102.19 million, a price-to-earnings ratio of -42.39 and a beta of 1.99. LifeMD has a 1 year low of $2.06 and a 1 year high of $6.24.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. As a group, research analysts predict that LifeMD will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Chapin Davis Inc. purchased a new position in shares of LifeMD during the third quarter worth about $29,000. State Street Corp grew its holdings in shares of LifeMD by 22.6% during the second quarter. State Street Corp now owns 1,318,784 shares of the company's stock worth $5,447,000 after buying an additional 243,376 shares during the last quarter. WINTON GROUP Ltd acquired a new position in LifeMD in the 2nd quarter valued at about $113,000. Integrated Wealth Concepts LLC acquired a new position in LifeMD in the 2nd quarter valued at about $25,000. Finally, Penn Capital Management Company LLC acquired a new position in LifeMD in the 2nd quarter valued at about $926,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications.

Its services include virtual primary care and programs focused on areas such as weight management, men's health, women's health, dermatology and chronic-care support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.